## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dolly et al.	) I hereby certify that this correspondence is being deposited
••	) with the United States Postal Service with sufficient postage
Serial No.: 09/294,980	) as First Class Mail in an envelope addressed to:
Filed: April 19, 1999	Assistant Commissioner for Patents, Washington, D.C. 20231 on:
For: Compositions and Methods For	) Date of Deposit: <u>5/20/</u> 49
Modulating Neural Sprouting	Person making Deposit: BONNIE FERGUSON
	) Signature of person making deposit:: Burnie fenge So
	) Date of Signature: <u>5/20/99</u>
Examiner: Not Assigned	) ,
Group Art Unit: Not Assigned	)
-	)

## INFORMATION DISCLOSURE STATEMENT

Box: Information Disclosure Statement-No Fee

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

## Dear Sir:

Applicant herewith submits form PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentablility of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Copies of references newly referenced in this Information Disclosure Statement are submitted herewith.

As this Information Disclosure Statement is being submitted prior to three months after the filing date of this Application, no fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

Date: 5 19 99

Carlos A. Fisher Reg. No. 36,510 ALLERGAN, INC.

T2-2E

2525 Dupont Drive Irvine, CA 92612

Tel: 714-246-4920 Fax: 714-246-4249

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

Sheet	_1_	of	_1
-------	-----	----	----

## LIST OF PRIOR ART CITED BY APPLICANT

ATTY. DOCKET:	SERIAL NO.:
17259(AP)	09/294,980
APPLICANT: Dolly et al	TITLE: COMPOSITIONS AND METHODS FOR MODULATING NEURAL SPROUTING
FILING DATE:	GROUP:
APRIL 19, 1999	NOT ASSIGNED
L	II S PATENT DOCUMENTS

			U.D. I AILI	I DOCCIVALITY			
*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA		L				
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AH	95/32738	12/7/1995	PCT			

OTHER PRIOR ART

		O I HER I HORIANI
		(Including Author, Title, Date, Pertinent Pages, etc.)
	TATI	J. Dutton, "Acute and Chronic Effects of Botulinum Toxin in the Management of Blepharospasm", Neurological Disease and Therapy.
,	1	pgs. 199-209, 25 (Jankovic J. & Hallett M. eds. 1994)
	AU	Tonello et al, "Tetanus and Botulism Neurotoxins a Novel Group of Zinc-Endopeptidases", Adv. Exp. Med. & Biol. 388: pgs. 251-260 (1996)
	AV	Coffield et al., "The Site and Mechanism of Action of Botulinum Neurotoxin", Neurological Disease and Therapy, pgs. 3-13, 25 (Jankovic J. & Hallett M. eds. 1994)
	AW	Araki et al, "Mechanism of Homophilic Binding Mediated by Ninjurin, a Novel Widely Expressed Adhesion Molecule", The Journal of Biological Chemistry, Vol. 272, No. 34, pgs. 21373-21380 (1997)
	AY	Caroni et al, "Role of Muscle Insulin-like Growth Factors in Nerve Sprouting: Suppression of Terminal Sprouting in Paralyzed Muscle by IGF-binding Protein 4", The Journal of Cell Biology, Vol. 125, No. 4, pgs. 893-902 (1994)
	AZ	Caroni et al, The Journal of Neuroscience, "Signaling by Insulin-like Growth Factors in Paralyzed Skeletal Muscle: Rapid Induction of IGF1 Expression in Muscle Fibers and Prevention of Interstitial Cell Proliferation by IGF-BP5 and IGF-BP4", 14: pgs. 3378-3388 (1994)
	BA	Ruegg et al, Trends Neurosci. *Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction*, 21: pgs. 22-27 (1998)
	BB	DePaiva et al, "Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their terminals", Proc. Nat'l Acad. Sci. USA, Vol. 96: pgs. 3200-3205(March 1999)
	BC	T. Cech, Current Opinion in Structural Biology, "Ribozyme engineering", 2: pgs. 605-609 (1992)
	BD	Borrodic et al, "Pharmacology and Histology of the Therapeutic Application of Botulinum Toxin, pgs. 119-157, Chapter 10, Therapy with Botulinum Toxin (Jankovic J. & Hallett M. eds. 1994)
	BE	Usman et al, Nucleic Acids & Molecular Biology, "Design, Synthesis, and Function of Therapeutic Hammerhead Ribozymes", Vol. 10: pgs. 243-264 (1996)
-	BF	Uherek et al, "A Modular DNA Carrier Protein Based on the Structure of Diphthena Toxin Mediates Target Cell-specific Gene Delivery", The Journal of Biological Chemistry, Vol. 273, No. 15, pgs. 8835-8841(1998)
	BG	Nedivi et al, "Promotion of Dendritic Growth by CPG15, an Activity-Induced Signaling Molecule", Science Vol. 281, 18 September 1998, pgs. 1863-1866
<b>EXAMINE</b>	R	DATE CONSIDERED
T/2 TT 11/11/11/11/11/11/11/11/11/11/11/11/11/	^ <u>`</u>	the state of the s

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.